Abstract

Modern management of hereditary angioedema (HAE) due to reduced C1 inhibitor (C1-INH) function or concentration (HAE-C1-INH) focuses on individualized therapeutic strategies to address the specific needs of children and adolescents as well as the severity of the disease. Psychosocial factors such as the burden of disease and therapy on quality of life and participation play an important role. New medications have already significantly improved the prognosis and health related quality of life in HAE patients, but not all of these therapies have yet been approved for children. Further treatment options that inhibit bradykinin effects are currently being investigated. They target factor XIIa, prekallikrein, plasma kallikrein, or the bradykinin B2 receptor. Modern research focuses on oral options or long-acting parenteral therapy approaches to further optimize care and, in particular, the needs of children. There are also initial developments in the field of gene therapy, which could represent a causal treatment option for HAE in the future.

Author Details

Authors

• Maria Fasshauer¹
• Bettina Wedi²

Departments

• ¹ Klinikum St. Georg Leipzig, Clinic for Pediatrics and Adolescent Medicine, ImmunDefektCentrum Leipzig (IDCL), Leipzig, and
• ² Hannover Medical School (MHH), Department of Dermatology, Allergology and Venereology, Interdisciplinary Allergy Center of the MHH, Treatment Center for Hereditary Angioedema of the MHH, Hannover, Germany

Address

Dr. med. Maria Fasshauer, Klinikum St. Georg Leipzig, Clinic for Pediatrics and Adolescent Medicine, ImmunDefektCentrum Leipzig (IDCL), Delitzscher Str. 141, 04129 Leipzig, Germany
Email: [email protected]

Citation